Two days, two landmark presentations at the #EASLCongress, two @nejm papers, and a whole lotta progress toward better therapies for #MASH with #survodutide and #tirzepatide.
HT: @danieljdrucker @boehringer @elilillyandco
https://conscienhealth.org/2024/06/survodutide-and-tirzepatide-dash-for-a-splash-with-mash/

Are we finally seeing progress in the development of better treatment options for #MASH? Topline results with #survodutide on top of pivotal results with #resmetirom in NEJM suggest we are.
https://conscienhealth.org/2024/02/progress-reported-in-mash-with-survodutide/